Wedbush Reiterates an 'Outperform' on Halozyme Therapeutics (HALO); Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued
Go back to Wedbush Reiterates an 'Outperform' on Halozyme Therapeutics (HALO); Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 98.66 -2.01 (2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.67 | 52 Week High | $18.39 | |||
| Open | $100.35 | 52 Week Low | $6.96 | |||
| Day High | $100.83 | P/E | N/A | |||
| Day Low | $98.13 | EPS | $-0.58 | |||
| Volume | 1,659,274 | |||||
